Harnessing the power of the immune system to fight cancer through research into cancer immune surveillance and chemo/immunotherapy, defining key cells and molecules that can elicit an effective response to tumours.
We are interested in the very early stages of how immune cells can pick up and respond to the presence of cancer cells. We have demonstrated that specific toxins made by “killer T cells” can prevent the onset of certain cancers (immune surveillance), and are developing genetic technologies to modify and expand the activity of these cells to treat established malignancies. In addition, we are defining the molecular means by which new classes of anti-cancer drugs kill cancer cells, so that rational choices can be made on the most appropriate cancer chemotherapy for a patient.
